Last reviewed · How we verify
Epoetin 4000
At a glance
| Generic name | Epoetin 4000 |
|---|---|
| Sponsor | Future University in Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients. (PHASE3)
- The Efficacy of Erythropoietin Oral Gel Versus Erythropoietin Mouthwash in the Management of Recurrent Aphthous Stomatitis (PHASE4)
- PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag). (PHASE3)
- Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company (PHASE1)
- Traumatic Optic Neuropathy Treatment Trial 2 (PHASE3)
- Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients (PHASE3)
- Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects. (PHASE1)
- Erythropoietin Role in Acute Kidney Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin 4000 CI brief — competitive landscape report
- Epoetin 4000 updates RSS · CI watch RSS
- Future University in Egypt portfolio CI